TrialClinical pharmacokinetics2016

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.

Erik Mogalian et al.PubMed ↗Publisher ↗

No numbers read from the abstract.